Title

PET Radiochemistry and Radiopharmacy Core

Rebekka Hueting, Core Leader

The PET Radiochemistry and Radiopharmacy core supports radiochemistry-dependent research programmes and provide GMP-grade PET radiopharmaceuticals for clinical trials.

Email: 
rebekka.hueting@oncology.ox.ac.uk

Research Summary

Currently under construction, the PET Radiochemistry and Radiopharmacy Core will be located at the Churchill Hospital alongside the PET-CT centre to enable translational research of radiotracers between the Department of Oncology and the Oxford University Hospitals NHS Trust.

The research and development labs will offer specialist radiosynthesis equipment, allowing the development of radiotracers and their production for in vitro and preclinical research.  We will transfer innovative radiochemistry protocols developed by our collaborators in chemistry to widen the portfolio of radiotracers available for biological evaluation.

Radiotracers for human administration will be produced in the Good Manufacturing Practice (GMP) labs since they must fulfil strict criteria for patient use. The facility and its team will provide proven PET imaging agents for trials and develop, validate and manufacture new tracer candidates.

Biography

Rebekka Hueting joined the Department of Oncology in 2014 to establish the PET Radiochemistry and Radiopharmacy Core. She obtained her DPhil on the synthesis of radiotracers for oncology and held a postdoctoral research fellowship at Kings College London and Oxford.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
Research
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.